FOR IMMEDIATE RELEASE: DALLAS (OCTOBER 8, 2020)… The United States Patent and Trademark Office has granted CTL Amedica Corporation patent number 10,765,529 for articulating intervertebral devices, related tools, systems and methods.
CTL Amedica’s newly patented system solves many complex challenges that are associated with traditional transforaminal lumbar interbody fusion (TLIF), an operation performed on the lower back to remove intervertebral disc material and join two or more vertebrae together using screws and interbody cages. In particular, the placement of a curved TLIF cage is often more challenging, given the overall implant footprint. CTL Amedica’s technology provides surgeons with an articulating implant insertion tool that is streamlined, innovative and dynamic. It allows for minimum tissue disruption, controlled re-positioning and more efficient deployment of compatible, curved TLIF cages.
“When a minimally invasive TLIF is performed, direct visualization of the disc space isn’t available during implantation. Lack of visualization may make proper implant placement extremely difficult and labor-intensive,” explains Daniel Chon, CTL Amedica president and CEO. “That’s why we partnered with Dr. Nitin Kukkar and Jon Wing to co-develop these instruments – as an innovative solution to the complex challenges of TLIF procedures.”
The TLIF instruments include articulating options that allow a greater range of interbody movement during the insertion period, as well as a preferred entry angle into the prepared disc space.
CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. In addition, it is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates unique bacteriostatic properties, provides superior imaging across all modalities and promotes an enhanced osteogenic response. For more information, visit https://www.ctlamedica.com/.
